Tag: Somatostatin
![telotristat etiprate clinical trial](https://www.carcinoid.org/wp-content/uploads/2013/11/telotristat-etiprate-clinical-trial.jpg)
Discover Something New in Carcinoid Syndrome
For patients who suffer from carcinoid syndrome – with symptoms such as diarrhea, frequent bowel movements, abdominal pain, and flushing – that is not adequately controlled by their current somatostatin analog therapy, there is an opportunity to participate…
READ MORE![pablo lapuerta md](https://www.carcinoid.org/wp-content/uploads/2012/11/pablo-lapuerta-md.jpg)
Lexicon Pharmaceuticals Begins Phase 3 Clinical Trial of Telotristat Etiprate in Patients with Carcinoid Syndrome
Patients with metastatic carcinoid syndrome will have the opportunity to participate in a new Phase 3 clinical trial of Lexicon Pharmaceutical’s telotristat etiprate (LX1032), an oral drug candidate designed to treat carcinoid syndrome by reducing…
READ MORE![Zebra](https://www.carcinoid.org/wp-content/uploads/2011/06/zebra.jpg)
Now Recruiting: Carcinoid Syndrome Patients to Participate in Clinical Trial
Ipsen is recruiting patients with a history of carcinoid syndrome to participate in a clinical study to evaluate the effect of Somatuline® Depot (Lanreotide Autogel), a somatostatin analog (SSTa) similar to octreotide, on the control of symptoms …
READ MORE